Income statement, balance sheet and cash flow statement for the last 4 fiscal years, taken from the XBRL data ASP Isotopes Inc. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2022
FY2023
FY2024
FY2025
Revenue
0
0.43
4.14
23.8
Cost of revenue
0
0.29
2.55
20.4
Gross profit
0
0.14
1.6
3.41
Research and development
1.27
0.76
3.14
12.4
General and administrative
3.83
15.4
24.8
48.2
Operating expenses
5.1
16.2
28
63.3
Operating income
-5.1
-16
-26.4
-59.9
Interest expense
0
0.12
0.26
0.58
Interest income
0
0.01
1.24
6.79
Other non-operating income
0.15
-0.26
-5.96
-99.7
Pre-tax income
-4.95
-16.3
-32.3
-160
Income tax
0
-0.01
0.11
0.28
Net income to minority interests
0
-0.01
Net income
-4.95
-16.3
-32.4
-160
EBITDA
-5.1
-16
-25.9
-58
EPS, basic
-0.18
-0.49
-0.63
-2.11
EPS, diluted
-0.18
-0.49
-0.63
-2.11
Shares, basic (weighted)
26.8
33.1
55.7
83
Shares, diluted (weighted)
26.8
33.1
55.7
83
Balance sheet
FY2022
FY2023
FY2024
FY2025
Cash and equivalents
2.39
7.91
61.9
280
Short-term investments
0
47.7
Receivables
0.22
Inventory
0
0.07
1.1
Other current assets
0.91
1.66
3.05
4.95
Total current assets
3.3
10.5
65.7
400
Property, plant and equipment
8.2
10.7
22.4
33.3
Lease right-of-use assets
0.85
1.26
1.12
1.46
Goodwill
0
3.27
3.17
5.18
Intangible assets
0.68
Other non-current assets
0.14
1.79
1.93
0.87
Total assets
12.5
27.5
94.3
498
Accounts payable
1.35
1.11
1.02
3.81
Accrued liabilities
0.36
1.31
2.28
4.41
Deferred revenue
0.88
0.87
Short-term debt
0.94
0.58
Total current liabilities
1.94
5.67
7.06
32.7
Long-term debt
0
1.44
1.47
Lease liabilities
0.74
1.07
0.69
1.06
Other non-current liabilities
0
1.65
0
0
Total liabilities
2.68
8.71
43.2
235
Total debt
2.38
2.06
Paid-in capital
16.8
40.6
106
432
Retained earnings
-7.55
-23.8
-56.2
-231
Treasury stock
0
Other comprehensive income
0.26
-0.92
-2.16
2.54
Shareholders' equity
9.82
16.3
47.9
204
Minority interests
0
2.53
3.27
58.7
Total equity
9.82
18.8
51.2
263
Total liabilities and equity
12.5
27.5
94.3
498
Shares outstanding
35.9
48.9
72.1
112
Cash flow statement
FY2022
FY2023
FY2024
FY2025
Net income
-4.95
-16.3
-32.4
-160
Depreciation and amortization
0
0.04
0.47
1.91
Stock-based compensation
2
8.74
8.56
16
Deferred income tax
0
0.02
-0.14
-0.05
Change in receivables
0.24
-0.51
-0.48
Change in inventory
0
-0.07
-0.32
Change in payables
0.57
-0.22
-0.88
0.78
Cash from operations
-2.94
-5.41
-16.7
-37.8
Capital expenditures
-4.47
-2.33
-9.68
-9.65
Purchases of investments
0
-47.7
Cash from investing
-4.47
-2.45
-11.4
-111
Debt issued
0
0.53
0.5
15.5
Debt repaid
-0.61
-15.8
Stock issued
8.12
14.1
53.1
320
Dividends paid
0
-2.78
0
Cash from financing
6.64
13.4
82.5
372
Exchange rate effect
0.21
-0
-0.48
0.65
Net change in cash
-0.77
5.52
54.5
223
Free cash flow
-7.41
-7.74
-26.4
-47.4
Income taxes paid
0
0.08
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $2.93 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Gross margin
18.3%
Gross profit / revenue.
Operating margin
-321.1%
Operating income / revenue.
EBITDA margin
-303.3%
EBITDA (operating income + depreciation and amortization) / revenue.
Pre-tax margin
-443.4%
Pre-tax income / revenue.
Net margin
-380.3%
Net income / revenue.
FCF margin
-270.9%
Free cash flow (cash from operations - capital expenditures) / revenue.
Operating cash flow margin
-219.8%
Cash from operations / revenue.
Return on equity (ROE)
-44.3%
Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)
-20.5%
Net income / average total assets.
Return on invested capital (ROIC)
-74.6%
Approximation: operating income x (1 - tax rate) / average (total debt + equity - cash). Tax rate is the effective rate when between 0% and 50%, else 21%.
R&D / revenue
71.4%
Research and development expense / revenue.
Stock-based pay / revenue
60.5%
Stock-based compensation (from the cash flow statement) / revenue.
Capex / revenue
51.1%
Capital expenditures / revenue.
D&A / revenue
17.8%
Depreciation and amortization / revenue.
Growth
Metric
Value
How it is calculated
Revenue growth, 1y
475.5%
Revenue vs the same period a year earlier. Only from a positive base.
Gross profit growth, 1y
112.9%
Gross profit vs the same period a year earlier. Only from a positive base.
Book value growth, 1y
326.2%
Book value vs the same period a year earlier. Only from a positive base.
Book value CAGR, 3y
175.0%
Compound annual growth of book value over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets growth, 1y
427.9%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
241.6%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Share count change, 1y
49.1%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y
45.8%
Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
3.87x
Current assets / current liabilities.
Quick ratio
3.63x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
3.63x
(Cash + short-term investments) / current liabilities.
Debt / equity
0.23x
Total debt / shareholders' equity. Not shown when equity is negative.
Debt / assets
10.4%
Total debt / total assets.
Liabilities / assets
52.0%
Total liabilities / total assets.
Net debt
-$195.1M
Total debt - cash - short-term investments. Negative means more cash than debt.
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Revenue per share
$0.25
Revenue / diluted weighted shares.
FCF per share
-$0.68
Free cash flow / diluted weighted shares.
Operating cash flow per share
-$0.55
Cash from operations / diluted weighted shares.
Book value per share
$2.03
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/S
14.5x
Market cap / revenue.
P/B
1.69x
Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book
1.74x
Market cap / tangible book value, when positive.
EV/Sales
8.21x
Enterprise value / revenue.
FCF yield
-18.6%
Free cash flow / market cap.
Earnings yield
-26.2%
Net income / market cap (the inverse of P/E).
What was ASP Isotopes Inc.'s revenue in fiscal 2025?
ASP Isotopes Inc. reported revenue of $23.8M for fiscal 2025, 475.5% higher than the year before.
Was ASP Isotopes Inc. profitable in fiscal 2025?
No. It reported a net loss of $159.8M.
How much free cash flow did ASP Isotopes Inc. generate in fiscal 2025?
Cash from operations of $37.8M minus capital expenditures of $9.7M left free cash flow of -$47.4M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.